Suppr超能文献

胆汁盐稳态激素成纤维细胞生长因子19在肝外胆汁淤积患者肝脏中的高表达。

High expression of the bile salt-homeostatic hormone fibroblast growth factor 19 in the liver of patients with extrahepatic cholestasis.

作者信息

Schaap Frank G, van der Gaag Niels A, Gouma Dirk J, Jansen Peter L M

机构信息

AMC Liver Center, Amsterdam, The Netherlands.

出版信息

Hepatology. 2009 Apr;49(4):1228-35. doi: 10.1002/hep.22771.

Abstract

UNLABELLED

Fibroblast growth factor 19 (FGF19) is an endocrine factor produced by the small intestine in response to uptake of luminal bile salts. In the liver, FGF19 binds to FGF receptor-4, resulting in down-regulation of cytochrome P (CYP) 7A1 and reduced bile salt synthesis. Down-regulation of CYP7A1 under cholestatic conditions has been attributed to bile salt-mediated induction of the transcriptional repressor short heterodimer partner (SHP), because the interrupted enterohepatic cycle of bile salts is thought to abrogate intestinal FGF19 production and thus result in lowering of plasma FGF19 levels. Unexpectedly, we observed marked elevation of plasma FGF19 in patients with extrahepatic cholestasis caused by a pancreatic tumor (2.3 +/- 2.3 in cholestatic versus 0.40 +/- 0.25 ng/mL and 0.29 +/- 0.12 ng/mL in postcholestatic patients who received preoperative drainage by biliary stenting, P = 0.004, and noncholestatic control patients, P = 0.04, respectively). Although FGF19 messenger RNA (mRNA) is virtually absent in normal liver, FGF19 mRNA was strongly increased (31-fold to 374-fold, P < 0.001) in the liver of cholestatic patients in comparison with drained and control patients. In the absence of changes in SHP mRNA, CYP7A1 mRNA was strongly reduced (7.2-fold to 24-fold, P < 0.005) in the liver of cholestatic patients in comparison with drained and control patients, indicating an alternative regulatory pathway. Alterations in transcripts encoding hepatobiliary transporters [adenosine triphosphate-binding cassette, subfamily C, member 3 (ABCC3)/multidrug resistance protein 3 (MRP3), organic solute transporter alpha/beta (OSTalpha/beta), organic anion-transporting polypeptide (OATP1B1)] further suggest that bile salts are secreted via a nonbiliary route in patients with extrahepatic cholestasis.

CONCLUSION

The liver expresses FGF19 under conditions of extrahepatic cholestasis. This is accompanied by a number of adaptations aimed at protecting the liver against bile salt toxicity. FGF19 signaling may be involved in some of these adaptations.

摘要

未标记

成纤维细胞生长因子19(FGF19)是小肠在摄取肠腔胆汁盐时产生的一种内分泌因子。在肝脏中,FGF19与FGF受体4结合,导致细胞色素P(CYP)7A1下调并减少胆汁盐合成。胆汁淤积条件下CYP7A1的下调归因于胆汁盐介导的转录抑制因子短异二聚体伴侣(SHP)的诱导,因为胆汁盐的肝肠循环中断被认为会消除肠道FGF19的产生,从而导致血浆FGF19水平降低。出乎意料的是,我们观察到由胰腺肿瘤引起的肝外胆汁淤积患者血浆FGF19显著升高(胆汁淤积患者为2.3±2.3,而接受术前胆道支架引流的胆汁淤积后患者为0.40±0.25 ng/mL和0.29±0.12 ng/mL,P = 0.004,非胆汁淤积对照患者为P = 0.04)。虽然正常肝脏中几乎不存在FGF19信使核糖核酸(mRNA),但与引流患者和对照患者相比,胆汁淤积患者肝脏中的FGF19 mRNA强烈增加(31倍至374倍,P < 0.001)。在SHP mRNA没有变化的情况下,与引流患者和对照患者相比,胆汁淤积患者肝脏中的CYP7A1 mRNA强烈减少(7.2倍至24倍,P < 0.005),表明存在另一种调节途径。编码肝胆转运蛋白[三磷酸腺苷结合盒,C亚家族,成员3(ABCC3)/多药耐药蛋白3(MRP3)、有机溶质转运体α/β(OSTα/β)、有机阴离子转运多肽(OATP1B1)]的转录本的改变进一步表明,肝外胆汁淤积患者的胆汁盐是通过非胆汁途径分泌的。

结论

肝外胆汁淤积时肝脏表达FGF19。这伴随着一系列旨在保护肝脏免受胆汁盐毒性的适应性变化。FGF19信号传导可能参与其中一些适应性变化。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验